AET01_AESI
Table 1 (Default) Adverse Event of Special Interest Summary Table.
aet01_aesi.Rd
AET01_AESI
Table 1 (Default) Adverse Event of Special Interest Summary Table.
Usage
aet01_aesi_main(
adam_db,
arm_var = "ACTARM",
lbl_overall = NULL,
aesi_vars = NULL,
grade_groups = NULL,
...
)
aet01_aesi_pre(adam_db, ...)
aet01_aesi_post(tlg, prune_0 = FALSE, ...)
aet01_aesi
Arguments
- adam_db
(
list
ofdata.frames
) object containing theADaM
datasets- arm_var
(
string
) variable used for column splitting- lbl_overall
(
string
) label used for overall column, if set toNULL
the overall column is omitted- aesi_vars
(
character
) theAESI
variables to be included in the summary. Defaults toNA
.- grade_groups
(
list
) the grade groups to be displayed.- ...
not used.
- tlg
(
TableTree
,Listing
orggplot
) object typically produced by amain
function.- prune_0
(
flag
) remove 0 count rows
Functions
aet01_aesi_main()
: Main TLG functionaet01_aesi_pre()
: Preprocessingaet01_aesi_post()
: Postprocessing
Note
adam_db
object must contain anadae
table with columns"AEOUT"
,"AEACN"
,"AECONTRT"
,"AESER"
,"AREL"
, and the column specified byarm_var
.aesi_vars
may contain any/all of the following variables to display:"ALLRESWD"
,"ALLRESDSM"
,"ALLRESCONTRT"
,"NOTRESWD"
,"NOTRESDSM"
,"NOTRESCONTRT"
,"SERWD"
,"SERDSM"
,"SERCONTRT"
,"RELWD"
,"RELDSM"
,"RELCONTRT"
,"RELSER"
.-
aesi_vars
variable prefixes are defined as follows:"ALLRES"
= "all non-fatal adverse events resolved""NOTRES"
= "at least one unresolved or ongoing non-fatal adverse event""SER"
= "serious adverse event""REL"
= "related adverse event"
-
aesi_vars
variable suffixes are defined as follows:"WD"
= "patients with study drug withdrawn""DSM"
= "patients with dose modified/interrupted""CONTRT"
= "patients with treatment received"
-
Several
aesi_vars
can be added to the table at once:aesi_vars = "ALL"
will include all possibleaesi_vars
.Including
"ALL_XXX"
inaesi_vars
whereXXX
is one of the prefixes listed above will include allaesi_vars
with that prefix.
Examples
run(aet01_aesi, syn_data)
#> A: Drug X B: Placebo C: Combination
#> (N=134) (N=134) (N=132)
#> ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
#> Total number of patients with at least one AE 122 (91.0%) 123 (91.8%) 120 (90.9%)
#> Total number of AEs 609 622 703
#> Total number of patients with at least one AE by worst grade
#> Grade 1 7 (5.2%) 9 (6.7%) 4 (3.0%)
#> Grade 2 6 (4.5%) 10 (7.5%) 7 (5.3%)
#> Grade 3 18 (13.4%) 14 (10.4%) 16 (12.1%)
#> Grade 4 15 (11.2%) 20 (14.9%) 18 (13.6%)
#> Grade 5 (fatal outcome) 76 (56.7%) 70 (52.2%) 75 (56.8%)
#> Total number of patients with study drug withdrawn due to AE 27 (20.1%) 26 (19.4%) 30 (22.7%)
#> Total number of patients with dose modified/interrupted due to AE 66 (49.3%) 76 (56.7%) 74 (56.1%)
#> Total number of patients with treatment received for AE 98 (73.1%) 102 (76.1%) 103 (78.0%)
#> Total number of patients with all non-fatal AEs resolved 84 (62.7%) 92 (68.7%) 97 (73.5%)
#> Total number of patients with at least one unresolved or ongoing non-fatal AE 102 (76.1%) 110 (82.1%) 107 (81.1%)
#> Total number of patients with at least one serious AE 104 (77.6%) 101 (75.4%) 99 (75.0%)
#> Total number of patients with at least one related AE 105 (78.4%) 108 (80.6%) 109 (82.6%)